Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Change in Receivables (2016 - 2025)

Corcept Therapeutics' Change in Receivables history spans 10 years, with the latest figure at -$9.8 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 71.45% year-over-year to -$9.8 million; the TTM value through Dec 2025 reached $5.8 million, down 54.8%, while the annual FY2025 figure was $5.8 million, 54.8% down from the prior year.
  • Change in Receivables for Q4 2025 was -$9.8 million at Corcept Therapeutics, down from $5.1 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $20.4 million in Q1 2024 and bottomed at -$9.8 million in Q4 2025.
  • The 5-year median for Change in Receivables is $1.4 million (2022), against an average of $1.7 million.
  • The largest YoY upside for Change in Receivables was 1259.67% in 2024 against a maximum downside of 191925.0% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $1.1 million in 2021, then soared by 47.09% to $1.6 million in 2022, then soared by 295.44% to $6.5 million in 2023, then plummeted by 188.36% to -$5.7 million in 2024, then plummeted by 71.45% to -$9.8 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Change in Receivables are -$9.8 million (Q4 2025), $5.1 million (Q3 2025), and $2.7 million (Q2 2025).